Drugs / Tdap
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02868970 | Feb 2017 → Jul 2021 | — | Canadian Immunization Research Network | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-10 | GlaxoSmithKline | Regulatory US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗
We’re immensely proud to have the first-ever Tdap vaccine approved by the FDA specifically for this use during pregnancy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-10 | GlaxoSmithKline | US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02868970 ↗ |
| Modality | Vaccine | “Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).” NCT02868970 ↗ |